Sunshine Biopharma- Warrants (15/02/2027) Long Term Debt

As of the most recent data (March 2026), SBFMW shows a long-term debt of $540K. That compares with $720K in the prior-year period — down 25.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBFMW's long-term debt is now $540K (was $720K) — a 25.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Sunshine Biopharma- Warrants (15/02/2027) is outperforming or lagging.

Tracking SBFMW's long-term debt over time shows whether Sunshine Biopharma- Warrants (15/02/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $540K That compares with $720K in the prior-year period — down 25.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Sunshine Biopharma- Warrants (15/02/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $540K) with ownership activity and broader fundamentals.

Sunshine Biopharma- Warrants (15/02/2027)'s long-term debt is $540K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.